NMS-P118

CAS No. 1262417-51-5

NMS-P118( NMS-P118 | NMS-P 118 | NMS P118 )

Catalog No. M11093 CAS No. 1262417-51-5

A potent and highly selective PARP-1 inhibitor with Kd of 9 nM; shows 150-fold selectivity for PARP-1 over PARP-2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 92 In Stock
5MG 93 In Stock
10MG 148 In Stock
25MG 297 In Stock
50MG 458 In Stock
100MG 666 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NMS-P118
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent and highly selective PARP-1 inhibitor with Kd of 9 nM; shows 150-fold selectivity for PARP-1 over PARP-2.
  • Description
    A potent and highly selective PARP-1 inhibitor with Kd of 9 nM; shows 150-fold selectivity for PARP-1 over PARP-2; exhibits excellent ADME and pharmacokinetic profiles and high efficacy in MDA-MB-436 and Capan-1 xenograft models; orally available.Breast Cancer Preclinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    NMS-P118 | NMS-P 118 | NMS P118
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    PARP
  • Research Area
    Cancer
  • Indication
    Breast Cancer

Chemical Information

  • CAS Number
    1262417-51-5
  • Formula Weight
    395.4187
  • Molecular Formula
    C20H24F3N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 16 mg/mL
  • SMILES
    O=C(C1=CC(F)=CC(CN2C3CCN(C4CCC(F)(F)CC4)CC3)=C1C2=O)N
  • Chemical Name
    1H-Isoindole-4-carboxamide, 2-[1-(4,4-difluorocyclohexyl)-4-piperidinyl]-6-fluoro-2,3-dihydro-3-oxo-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Papeo G, et al. J Med Chem. 2015 Sep 10;58(17):6875-98.
molnova catalog
related products
  • AZD-9574

    AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies.

  • TIQ-A

    TIQ-A is a PARP1 inhibitor which involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.

  • Senaparib

    Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.